Autonomix Granted U.S. Patent No. 12,544,131
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Autonomix announced the United States Patent and Trademark Office has issued U.S. Patent No. 12,544,131. The newly granted patent covers catheter-based transvascular tools and systems designed to operate from within a bodily lumen, where deployable probes penetrate into and/or through a lumen wall to access tissue and nerves located outside the vessel. The patent includes claims relating to multi-site electrophysiological sensing, incorporating sensing at a target site, secondary site, and reference site to improve signal quality and procedural confidence. It also encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to assess treatment effect and procedural outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMIX
Wall Street analysts forecast AMIX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.415
Low
5.00
Averages
5.00
High
5.00
Current: 0.415
Low
5.00
Averages
5.00
High
5.00
About AMIX
Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Autonomix Medical Releases Latest CEO Corner Segment
- Publication Strategy: CEO Brad Hauser emphasizes that over the past 12 to 18 months, Autonomix Medical has focused on expanding its scientific publication and presentation footprint by submitting clinical and technical data to competitive, peer-reviewed forums, thereby enhancing clinical credibility and laying a foundation for long-term growth.
- Innovative Technology Platform: The company's first-in-class platform technology includes a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than current technologies, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time.
- Initial Trial Focus: Autonomix is initially developing this technology for treating pain associated with pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions, with initial trials paving the way for applications in cardiology, hypertension, and chronic pain management.
- Forward-Looking Statements: While Autonomix is optimistic about the potential effectiveness and clinical benefits of its nerve-targeted treatments, the company cautions investors about risks and uncertainties that could lead to significant differences between actual results and expectations, urging careful review of risk factors.
See More
Autonomix Medical to Present Long-Term Clinical Data at SSO 2026
- Clinical Data Presentation: Autonomix Medical will present long-term clinical data at the SSO Annual Meeting from March 5-7, 2026, where Clinical Development Engineer II Clarke Wilkirson, PhD, will highlight the potential of their minimally invasive transvascular RF energy-based ablation method in mitigating chronic pain for pancreatic adenocarcinoma patients.
- Technological Innovation: The company's first-in-class platform technology features a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than existing technologies, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time.
- Industry Impact: The SSO Annual Meeting convenes leading surgical oncologists and researchers to showcase advancements in surgical oncology and emerging clinical technologies, and Autonomix's participation is expected to enhance its visibility and influence within the medical device industry.
- Market Potential: Currently, the technology is undergoing initial trials focused on pancreatic cancer, with plans to expand into cardiology, hypertension, and chronic pain management, indicating a broad market application potential.
See More
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
- Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
- Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
- Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
- Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.
See More
FONAR Corporation Confirms Take-Private Deal, Shares Surge 28%
- Take-Private Confirmation: FONAR Corporation confirmed its take-private deal, leading to a 28% surge in shares to $18.82, reflecting strong market confidence that may provide the company with greater flexibility for future growth.
- Patent Approval Boost: Autonomix Medical, Inc. shares rose 30% to $0.6943 after the European Patent Office granted Patent No. EP4230133, indicating significant advancements in cardiac tissue treatment technology that could enhance its competitive position in the market.
- Return to Profitability: Cemtrex, Inc. saw a 40% increase in shares to $2.95 as the company announced a return to profitability despite ongoing going-concern warnings, showcasing investor optimism regarding its future prospects.
- Merger Agreement Impact: Flushing Financial Corporation shares fell 8% to $15.46 following the announcement of a merger agreement with OceanFirst Financial Corp. and a $225 million strategic investment, indicating mixed market reactions that could affect the future performance of both companies.
See More
Autonomix Secures European Patent, Expanding Cardiac Treatment Market
- Patent Grant: Autonomix Medical has been granted European Patent EP4230133, covering systems and methods for precise cardiac tissue treatment, further solidifying its strategic position in a multi-billion-dollar market.
- Technological Breakthrough: This patent involves feedback-driven neuromodulation and denervation techniques that can precisely sense and treat cardiac tissues, which is expected to significantly enhance treatment outcomes for high-burden diseases such as heart disease and hypertension.
- Market Potential: The patent not only strengthens Autonomix's technological protection in cardiology but also unlocks greater market opportunities in high-growth areas like renal denervation and arrhythmia management.
- Innovative Platform: Autonomix's first-in-class technology platform has the potential to address various diseases, including cardiology and chronic pain management, marking a significant advancement in the diagnosis and treatment of nervous system disorders.
See More
Autonomix Medical Advances Nerve-Targeted Treatment Technology
- Intellectual Property Protection: In the latest CEO Corner, Autonomix CEO Brad Hauser emphasized the company's strategy to strengthen its intellectual property, which will safeguard its competitive advantage in the medical device market and ensure ongoing leadership.
- New Market Exploration: The company plans to expand its nerve-targeted treatment technology beyond pancreatic cancer to include cardiovascular, pulmonary diseases, and chronic pain, a strategic shift that could open new revenue streams and enhance market share.
- Technological Innovation: Autonomix's microchip sensing array technology is expected to enable unprecedented transvascular diagnosis and treatment capabilities, significantly improving the diagnosis and treatment of peripheral nervous system diseases and meeting market demand for high-sensitivity technologies.
- Clinical Trial Progress: The company is currently conducting preliminary clinical trials focused on pancreatic cancer, and if successful, it will provide patients with a reliable pain management solution, further solidifying its market position in nerve treatment.
See More
Autonomix Medical Releases Latest CEO Corner Segment
- Publication Strategy: CEO Brad Hauser emphasizes that over the past 12 to 18 months, Autonomix Medical has focused on expanding its scientific publication and presentation footprint by submitting clinical and technical data to competitive, peer-reviewed forums, thereby enhancing clinical credibility and laying a foundation for long-term growth.
- Innovative Technology Platform: The company's first-in-class platform technology includes a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than current technologies, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time.
- Initial Trial Focus: Autonomix is initially developing this technology for treating pain associated with pancreatic cancer, a condition that causes debilitating pain and lacks reliable solutions, with initial trials paving the way for applications in cardiology, hypertension, and chronic pain management.
- Forward-Looking Statements: While Autonomix is optimistic about the potential effectiveness and clinical benefits of its nerve-targeted treatments, the company cautions investors about risks and uncertainties that could lead to significant differences between actual results and expectations, urging careful review of risk factors.
See More
Autonomix Medical to Present Long-Term Clinical Data at SSO 2026
- Clinical Data Presentation: Autonomix Medical will present long-term clinical data at the SSO Annual Meeting from March 5-7, 2026, where Clinical Development Engineer II Clarke Wilkirson, PhD, will highlight the potential of their minimally invasive transvascular RF energy-based ablation method in mitigating chronic pain for pancreatic adenocarcinoma patients.
- Technological Innovation: The company's first-in-class platform technology features a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than existing technologies, potentially enabling transvascular diagnosis and treatment of peripheral nervous system diseases for the first time.
- Industry Impact: The SSO Annual Meeting convenes leading surgical oncologists and researchers to showcase advancements in surgical oncology and emerging clinical technologies, and Autonomix's participation is expected to enhance its visibility and influence within the medical device industry.
- Market Potential: Currently, the technology is undergoing initial trials focused on pancreatic cancer, with plans to expand into cardiology, hypertension, and chronic pain management, indicating a broad market application potential.
See More
OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%
- Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
- Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
- Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
- Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.
See More
FONAR Corporation Confirms Take-Private Deal, Shares Surge 28%
- Take-Private Confirmation: FONAR Corporation confirmed its take-private deal, leading to a 28% surge in shares to $18.82, reflecting strong market confidence that may provide the company with greater flexibility for future growth.
- Patent Approval Boost: Autonomix Medical, Inc. shares rose 30% to $0.6943 after the European Patent Office granted Patent No. EP4230133, indicating significant advancements in cardiac tissue treatment technology that could enhance its competitive position in the market.
- Return to Profitability: Cemtrex, Inc. saw a 40% increase in shares to $2.95 as the company announced a return to profitability despite ongoing going-concern warnings, showcasing investor optimism regarding its future prospects.
- Merger Agreement Impact: Flushing Financial Corporation shares fell 8% to $15.46 following the announcement of a merger agreement with OceanFirst Financial Corp. and a $225 million strategic investment, indicating mixed market reactions that could affect the future performance of both companies.
See More
Autonomix Secures European Patent, Expanding Cardiac Treatment Market
- Patent Grant: Autonomix Medical has been granted European Patent EP4230133, covering systems and methods for precise cardiac tissue treatment, further solidifying its strategic position in a multi-billion-dollar market.
- Technological Breakthrough: This patent involves feedback-driven neuromodulation and denervation techniques that can precisely sense and treat cardiac tissues, which is expected to significantly enhance treatment outcomes for high-burden diseases such as heart disease and hypertension.
- Market Potential: The patent not only strengthens Autonomix's technological protection in cardiology but also unlocks greater market opportunities in high-growth areas like renal denervation and arrhythmia management.
- Innovative Platform: Autonomix's first-in-class technology platform has the potential to address various diseases, including cardiology and chronic pain management, marking a significant advancement in the diagnosis and treatment of nervous system disorders.
See More
Autonomix Medical Advances Nerve-Targeted Treatment Technology
- Intellectual Property Protection: In the latest CEO Corner, Autonomix CEO Brad Hauser emphasized the company's strategy to strengthen its intellectual property, which will safeguard its competitive advantage in the medical device market and ensure ongoing leadership.
- New Market Exploration: The company plans to expand its nerve-targeted treatment technology beyond pancreatic cancer to include cardiovascular, pulmonary diseases, and chronic pain, a strategic shift that could open new revenue streams and enhance market share.
- Technological Innovation: Autonomix's microchip sensing array technology is expected to enable unprecedented transvascular diagnosis and treatment capabilities, significantly improving the diagnosis and treatment of peripheral nervous system diseases and meeting market demand for high-sensitivity technologies.
- Clinical Trial Progress: The company is currently conducting preliminary clinical trials focused on pancreatic cancer, and if successful, it will provide patients with a reliable pain management solution, further solidifying its market position in nerve treatment.
See More
